Status:
COMPLETED
Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance
Lead Sponsor:
Ain Shams University
Conditions:
Heart Failure
Eligibility:
All Genders
50-70 years
Phase:
NA
Brief Summary
The aim of this study is to assess whether sacubitril-valsartan is more effective than dapagliflozin in improving function, myocardial performance in patients undergoing CABG operation or not
Detailed Description
Coronary revascularization has matured as a field since coronary artery bypass grafting (CABG) was first developed over 50 years ago, with diagnostic and treatment methods have advanced dramatically. ...
Eligibility Criteria
Inclusion
- Age between 50 to 70 years old
- DM type 2
- ASA 3
- Only 2 coronary grafts
- Elective surgery
- Bypass time less than 1 hour
- Senior staff cardiothoracic
Exclusion
- ASA 4 or more
- Emergency surgery
- Bypass time of more than 1 hour
- Coronary grafts of more than 2
- Any allergy to the used drugs
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06090487
Start Date
February 1 2024
End Date
March 1 2024
Last Update
September 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University
Cairo, Egypt